DEVELOPMENT OF ANALYTICAL METHODS FOR THE DETERMINATION OF METABOLITES OF CORTICOSTEROID DRUGS FOR THE FOLLOW-UP OF TREATMENTS. (Q3175620): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in en: translated_label)
(‎Removed claim: summary (P836): The starting hypothesis in this project is that there is a major problem in the design of therapeutic solutions for chronic diseases due to the lack of adherence to treatments, which can exceed 50 %. This often leads to a change of treatment, usually towards others with much higher prices or an increased risk to the patient’s health. Asthma is one of the chronic diseases that show such problems and administration of inhaled glucocorticoids (GC...)
Property / summary
The starting hypothesis in this project is that there is a major problem in the design of therapeutic solutions for chronic diseases due to the lack of adherence to treatments, which can exceed 50 %. This often leads to a change of treatment, usually towards others with much higher prices or an increased risk to the patient’s health. Asthma is one of the chronic diseases that show such problems and administration of inhaled glucocorticoids (GCI) is the most common treatment. The availability for the pneumologist of objective clinical analyses to know if the patient is undergoing treatment when he sees no progress in disease control is therefore very useful. The use of methods for the rapid determination of DAGs, or metabolites thereof, preferably based on immunoassay techniques, that allow their detection in plasma or/and urine, can be a tool for monitoring adherence to the most widely used DAGs (beclomethasone, budesonide and fluticasone) in asthmatic patients who are usually treated in specialised consultation. The first objective will be the development of instrumental methods (LC-MS) of detection in the laboratory that demonstrate the feasibility and effectiveness of this treatment monitoring, in order to validate the results obtained with the immunological methods developed in parallel, mainly ELISAs and lateral flow immunochromatography (LFIA). (English)
 
Property / summary: The starting hypothesis in this project is that there is a major problem in the design of therapeutic solutions for chronic diseases due to the lack of adherence to treatments, which can exceed 50 %. This often leads to a change of treatment, usually towards others with much higher prices or an increased risk to the patient’s health. Asthma is one of the chronic diseases that show such problems and administration of inhaled glucocorticoids (GCI) is the most common treatment. The availability for the pneumologist of objective clinical analyses to know if the patient is undergoing treatment when he sees no progress in disease control is therefore very useful. The use of methods for the rapid determination of DAGs, or metabolites thereof, preferably based on immunoassay techniques, that allow their detection in plasma or/and urine, can be a tool for monitoring adherence to the most widely used DAGs (beclomethasone, budesonide and fluticasone) in asthmatic patients who are usually treated in specialised consultation. The first objective will be the development of instrumental methods (LC-MS) of detection in the laboratory that demonstrate the feasibility and effectiveness of this treatment monitoring, in order to validate the results obtained with the immunological methods developed in parallel, mainly ELISAs and lateral flow immunochromatography (LFIA). (English) / rank
Normal rank
 
Property / summary: The starting hypothesis in this project is that there is a major problem in the design of therapeutic solutions for chronic diseases due to the lack of adherence to treatments, which can exceed 50 %. This often leads to a change of treatment, usually towards others with much higher prices or an increased risk to the patient’s health. Asthma is one of the chronic diseases that show such problems and administration of inhaled glucocorticoids (GCI) is the most common treatment. The availability for the pneumologist of objective clinical analyses to know if the patient is undergoing treatment when he sees no progress in disease control is therefore very useful. The use of methods for the rapid determination of DAGs, or metabolites thereof, preferably based on immunoassay techniques, that allow their detection in plasma or/and urine, can be a tool for monitoring adherence to the most widely used DAGs (beclomethasone, budesonide and fluticasone) in asthmatic patients who are usually treated in specialised consultation. The first objective will be the development of instrumental methods (LC-MS) of detection in the laboratory that demonstrate the feasibility and effectiveness of this treatment monitoring, in order to validate the results obtained with the immunological methods developed in parallel, mainly ELISAs and lateral flow immunochromatography (LFIA). (English) / qualifier
point in time: 12 October 2021
Timestamp+2021-10-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 

Revision as of 18:29, 12 October 2021

Project Q3175620 in Spain
Language Label Description Also known as
English
DEVELOPMENT OF ANALYTICAL METHODS FOR THE DETERMINATION OF METABOLITES OF CORTICOSTEROID DRUGS FOR THE FOLLOW-UP OF TREATMENTS.
Project Q3175620 in Spain

    Statements

    country
    Spain
    0 references
    EU contribution
    468,741.6 Euro
    0 references
    budget
    585,927.0 Euro
    0 references
    co-financing rate
    80.0 percent
    0 references
    start time
    1 December 2018
    0 references
    end time
    30 November 2021
    0 references
    beneficiary name (string)
    BIOMEDAL, S.L.
    0 references
    beneficiary
    Q3169898
    0 references
    coordinate location

    37°24'7.24"N, 6°1'59.38"W
    0 references
    postal code
    41021
    0 references
    summary
    La hipótesis de partida que se plantea en este proyecto es que hay un gran problema en el diseño de soluciones terapéuticas de enfermedades crónicas por la falta de adherencia a los tratamientos, que puede superar el 50%. Esto conlleva en muchas ocasiones al cambio de tratamiento, habitualmente hacia otros con precios mucho mayores o a un aumento del riesgo en la salud del paciente. El asma es una de las enfermedades crónicas que muestran tales problemas y la administración de glucocorticoides inhalados (GCI) es el tratamiento más común. La disponibilidad para el médico neumólogo de analíticas clínicas objetivas para saber si el paciente está cumpliendo el tratamiento cuando no ve progresos en el control de la enfermedad es por tanto de gran utilidad. El uso de métodos para la determinación rápida de GCI, o metabolitos de los mismos, basados preferentemente en técnicas de inmunoensayos, que permitan su detección en plasma o/y orina, puede ser una herramienta para el seguimiento de adherencia a los GCI de más amplio uso (beclometasona, budesónida y fluticasona) en pacientes asmáticos atendidos habitualmente en consulta especializada. El primer objetivo será el desarrollo de métodos instrumentales (LC-MS)de detección en el laboratorio que demuestren la viabilidad y efectividad de dicha monitorización del tratamiento, para así validar los resultados obtenidos con losmétodos inmunológicos desarrollados en paralelo, principalmente ELISAs y inmunocromatografía de flujo lateral (LFIA). (Spanish)
    0 references
    location (string)
    Camas
    0 references

    Identifiers

    Spanish Kohesio ID
    IDI-20190261
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q3175620&oldid=12847149"